PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

G Proteins and Cancer

SBKB [doi:10.3942/psi_sgkb/fm_2013_11]
Featured System - November 2013
Short description: G-proteins play an essential role in cell signaling, a role that is corrupted in many types of cancer cells.

Miscommunication is the hallmark of cancer. Normally, our cells are in constant communication, deciding how to share resources, determining the best time to grow, and if necessary, the best time to die. Cancer cells, on the other hand, typically have corrupted these lines of communication, allowing them to grow without limits and selfishly steal resources for themselves. GPCRs (G-protein-coupled receptors) are among the many different molecules of communication that are changed when a normal cell is transformed into a cancer cell.

Cancer Survey

PSI researchers recently surveyed the genetic sequences of many diverse cancer cells and found that problems in the G protein signaling system are very common. Our genome encodes about 800 different GPCRs, and mutations in these are found in roughly one fifth of all cancers. Mutations in G-proteins, the proteins that relay GPCR signals inside the cell, are also very common in cancer cells.

Wrong Place at the Wrong Time

In some cases, the expression of a GPCR may be transformed in a cancer cell. For instance, CXCR4, shown here from PDB entry 3odu, is not normally found in breast cells, but is often found in breast cancer cells. CXCR4 normally helps to control the movement of cells in the immune system and during development. But when it's expressed in the wrong place, it can assist the movement of cancer cells, leading to metastasis.

Cancer Hotspots

Signaling through GPCRs occurs through subtle shifts of its helices, transmitting a signal from outside the cell to a G-protein inside. These shifts are seen in the two structures of the adrenergic receptor shown here on the left: an inactive form in green and an activated form in red, bound to a G-protein in blue (PDB entries 2rh1 and 3sn6). Two of the helices, shown here in bright green and red, show the largest motions when the signal is transmitted. As shown on the model at the right, the most common cancer-causing mutations (shown in turquoise) occur at the interfaces between these helices in a similar GPCR, the human thyroid stimulating hormone receptor, corrupting these essential motions.

Shooting the Messenger

Based on the PSI survey, the most common cancer causing mutations in G-proteins occur at the nucleotide-binding site of the alpha subunit. Two common sites of mutation are shown here in bright red, from PDB entry 1cul. This small change is enough to unhinge the normal control of the protein, which is usually turned "on" and "off" by the state of the bound nucleotide. To take a closer look at this interaction, the JSmol tab below displays an interactive JSmol.

G-protein and Adenylyl Cyclase (PDB entry 1cul)

This structure includes the alpha subunit of a G-protein (pink) bound to its signaling target, adenylyl cyclase (blue). The bound nucleotide is in green. The two amino acids in bright red, which form part of the nucleotide-binding site, are mutated in some forms of cancer.

References

  1. O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein- coupled receptors in cancer. Nat. Rev. Cancer 13, 412-424 (2013).

References to Structures

  1. Rassmussen, S. G. et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).

  2. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).

  3. Cherezov, V. et al. High-resolution crystal structure of an engineered human beta2- adrenergic G protein-coupled receptor. Science 318, 1258-1265 (2007).

  4. Tesmer, J. J. et al. Molecular basis for P-site inhibition of adenylyl cyclase. Biochem. 39, 14464-14471 (2000).

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health